ROADS CLINICAL STUDY for PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRAIN TUMORS | REFER A PATIENT

ROADS Clinical Study
for patients with newly diagnosed metastatic brain tumors

Do I Qualify For ROADS?

Have you, or someone you know, been newly diagnosed with a metastatic brain tumor?

If so, you should be aware of the opportunity to participate in the ROADS Clinical Study.

This important clinical study compares 2 FDA-cleared radiation treatments that are proven safe and effective: GammaTile® Surgically Targeted Radiation Therapy (STaRT) and stereotactic radiotherapy (SRT).

The ROADS Clinical Study is enrolling now at participating hospitals across the country.

Do you quality for the study?

  • Have been newly diagnosed with 1 or more operable metastatic brain tumors
  • Are aged 18 years or older
  • Are not pregnant or planning a pregnancy
  • Live near a participating hospital
  • Have not yet scheduled surgery, or surgery is scheduled for a week or more from today

For more information contact a participating hospitals or take the ROADS Patient Evaluation.

Patient Evaluation

Learn more about the ROADS clinical study

Overview

Metastatic brain tumors (also called secondary brain tumors) are caused by cancer cells that have metastasized or spread to the brain from a different part of the body.

Radiation therapy kills cancer cells and shrinks tumors. It is often combined with surgery and chemotherapy to help eliminate any remaining tumor cells and prevent the tumor from returning.1-3

The ROADS Clinical Study will provide more information about how effective GammaTile and SRT are at preventing brain tumor recurrence.

About the study

Study participants will be randomly divided into 2 treatment groups:

 

Following brain tumor removal surgery, clinical study participants will receive either GammaTile or SRT to the area where the tumor was.

Study participants in both groups may have additional brain tumors that may not be suitable for surgical removal. These remaining brain tumors will be treated with SRT.

Clinical Study FAQs

References:

  1. RT Answers Web site. https://rtanswers.org/How-does-radiation-therapy-work/Stereotactic-Radiation-Therapy. Accessed February 6, 2022.
  2. Brachman D, Youssef E, Dardis C, Smith K, Pinnaduwage D, Nakaji P. Surgically targeted radiation therapy: Safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. Brachytherapy. 2019;18(3):S35-S36.
  3. GammaTile Therapy Instructions for Use. Tempe, AZ. GT Medical Technologies; 2020.

The ROADS Study is sponsored by GT Medical Technologies, Inc., the makers of GammaTile. Please discuss the risks and benefits of participating in this clinical study with your care team.

Indications

GammaTile is indicated to deliver radiation therapy in patients with newly diagnosed malignant and recurrent brain tumors. Possible complications can occur with any neurosurgical procedure and include cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation. For full product and safety information, speak to your physician and refer to the instructions for use.

ROADS CLINICAL STUDY for PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRAIN TUMORS

ENROLLING NOW

©2022 GT Medical Technologies, Inc. I All rights reserved I GammaTile is a registered trademark of GT Medical Technologies, Inc.